The clinical trials below are available in the specialty you selected. Choose a different specialty.
Researchers are seeking healthy volunteers for participation in a study aimed at reducing the risk of heart disease and type 2 diabetes in at-risk individuals. (REF# 16540)
Adult ADHD Medication Study
A nationwide research study of a new investigational drug for adults with ADHD. Duke University Medical Center in Durham, NC, will conduct this study. Study-related evaluations and study drug will be provided at no cost to those who qualify. (REF# 00042466)
Nicotine, Non-Smokers with and without ADHD, and Genetics Study (NNSG)
The main purpose of the NNSG study is to evaluate the effects of nicotine exposure in a group of nonsmoking young adults with and without ADHD. (REF# Pro00037792)
ADHD Adolescent Medication Study
We are looking for adolescents 13-17 years old who may have ADHD to participate in a nationwide research study testing two FDA approved drugs for ADHD. ADHD evaluation and study drug will be provided at no cost to those who qualify. (REF# 00038164)
Neurobehavioral Research of HIV and Cocaine
The purpose is to examine neurobehavioral functioning in persons with HIV and/or cocaine dependence. The age range of our population is from 20 to 60 years old. The study includes up to 3 visits depending upon eligibility and participants can earn up to $180 for completion of all three study visits. The visits include a screening, a neuropsychological assessment visit, and an fMRI brain scan. No drugs or treatment are provided in this study. (REF# 00016338)
A Prospective, Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H-Coil deep Transcranial Magnetic Stimulation (dTMS) in Conjunction with Mood Stabilizers in Subjects with Bipolar Depression
A research study is being conducted at Duke University Medical Center to evaluate whether dTMS is safe and effective in treating bipolar depression in individuals who are currently taking mood stabilizers and previously have been treated unsuccessfully with antidepressant medications. (REF# Pro00034547)
We are currently enrolling participants (ages: 18-70) for a study to assess psychometric properties of novel neurocognitive measures. (REF# Pro00039288)
A Phase 3 Double-Blind Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder.
The purpose of this research study is to evaluate the efficacy (how well the drug works), safety and tolerability (the side effects) of cariprazine compared to placebo (an inactive substance) in subjects with major depressive disorder who are also receiving an approved antidepressant. (REF# Pro00040688)
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adults.
The purpose of this study is to determine if a new formulation of ramelteon (TAK-375SL) is effective in decreasing the symptoms of depression associated with bipolar I disorder so the study evaluates using an additional drug to your current medication to control depression in bipolar individuals. (REF# Pro00034212)
A Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 Tablet for Sublingual Administration in the Treatment of Acute Depressive Episodes
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg, 0.4 mg, and 0.8 mg in the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Patients who are on Lithium and/or Valproate (REF# Pro00034200)